logo
episode-header-image
Aug 4
25m 39s

Corner Office Conversation with The New ...

THE ECONOMIC TIMES
About this episode

India’s pharma sector is at a turning point transitioning from a global generics powerhouse to a serious contender in biotech and innovation. In this episode, host Vikas Dandekar is joined by Namita Thapar, Executive Director, Emcure Pharmaceuticals, Aman Mehta, Managing Director, Torrent Pharma, and Sharvil Patel, Managing Director, Zydus Lifesciences to explore what it takes to climb the innovation ladder. From regulatory roadblocks and pricing pressures to building a robust R&D ecosystem, the panel lays it all out. Patel reflects on Zydus’ early bet on research, Thapar shares Emcure’s commitment to women’s health and inclusive leadership, while Mehta highlights the shift toward patient-first thinking. Blending sharp insights, real-world data, and candid personal stories, this conversation asks the big question: Can India go from being the “pharmacy of the world” to becoming its “laboratory”?

You can follow Vikas Dandekar on his social media: Twitter and Linkedin and read her Newspaper Articles.

Listen to the first installment of Corner Office Conversation called Corner Office Conversation with Pawan Goenka, Chairman, IN-SPACe

Catch the latest episode of the new show “Corner Office Conversation” on: Spotify, Amazon Music, Apple Podcasts,and wherever you get your podcasts from.

See omnystudio.com/listener for privacy information.

Up next
Today
South Capital: Karnataka Grows Beyond Bengaluru
Karnataka drives 65% of India’s aerospace and defence output, over half of its machine tools, and 60% of its biotech exports but much of that growth is concentrated in and around Bengaluru. This week, we unpack the state’s broader industrial ambitions and historic legacy from the ... Show More
15m 59s
Yesterday
Ram Madhvani on Blending VR, AI and Bharat
Virtual Reality in India has long been seen as a futuristic gaming gimmick flashy, expensive, and niche. But that’s changing. Host Anirban Chowdhury and ETs Rajesh Naidu talk to national award winning film maker Ram Madhvani (Neerja, Aarya) who is reimagining VR as a cultural and ... Show More
24m 32s
Aug 5
US’ Tariff Blow: What can India Do?
What happens when economic friction between two global partners sparks deeper strategic questions? In this episode of The Morning Brief, host Anirban Chowdhury talks to Agneshwar Sen, trade policy leader, EY India, to unpack the implications of recent US tariff on India and threa ... Show More
26m 23s
Recommended Episodes
Jul 2024
Why executive pay is skyrocketing
Remuneration among CEOs in the US is rising quickly. It’s been hard to miss recent examples of massive pay packages, like for Tesla’s Elon Musk. But that growth is far outpacing that of wages for everyday workers in the US. The FT’s corporate governance reporter Patrick Temple-We ... Show More
22m 24s
Sep 2024
The Man Leading Amazon’s AI Reboot
Rohit Prasad was one of the chief architects of Amazon’s Alexa. Now, he’s leading the company’s effort to catch up in the AI race. WSJ reporter Sebastian Herrera joins host Zoe Thomas to discuss how Amazon slipped behind rivals like OpenAI and Google and what Prasad’s team is doi ... Show More
13m 31s
Apr 2025
SOTS 2nd Hour: Tariff Updates, Earnings Wrap-up, and Is This Rally Real? – plus: Coca-Cola CEO Talks Results 4/29/25
Fresh news on the tariff front when it comes to potential deals – and hopes of relief for the automakers… Carl Quintanilla, Sara Eisen, and David Faber broke down the latest from the White House, alongside the morning’s biggest earnings stories: from GM pulling guidance and delay ... Show More
42m 32s
Jan 2025
AI, vaccine distrust, and the future of healthcare: Novartis CEO
Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline i ... Show More
25m 45s
Feb 2025
US companies endure tariff whiplash
Alphabet’s cloud services missed growth expectations last quarter, American companies are scrambling to protect their supply chains in the face of all the back and forth on tariffs, and China is hitting back at the US for imposing new levies. Plus, India is set for a blockbuster ... Show More
10m 38s
Jan 2025
Why Nasdaq's CEO sees IPO market growth ahead: FROM DAVOS
The IPO market was mixed at best in 2024 despite strong showings by Reddit (RDDT), Viking (VIK), and Rubrik (RBRK). IPOs raised about $123 billion last year compared to a peak of $594 billion in 2021, according to Dealogic data. A total of 150 companies went public last year, per ... Show More
25m 38s
Oct 2017
Jeff Bezos Isn’t King
Shareholder returns aren’t the only barometer of CEO success anymore, or else Jeff Bezos would be on top. In recent years, sustainability and diversity have gained importance—and in those areas, European CEOs are lapping their American competitors. Adi Ignatius, editor in chief o ... Show More
29m 48s
May 5
What’s News in Earnings: Consumer Shakiness Worries Food and Drink Companies
Bonus Episode for May 5. Consumers are in belt-tightening mode. Many are buying less, reconsidering their purchases and feeling rattled by volatile markets and the Trump administration’s shape-shifting tariff policies. For soda makers like Pepsi and restaurant chains like McDonal ... Show More
9m 26s
Apr 2021
Stocks Fall Despite Amazon's Blowout Quarter, The Bulls Winning In April, Twitter Tumbles, and Apple vs. the EU
On the final trading day of what has been a strong April for stocks, Carl Quintanilla and Jim Cramer led off the show with a look at blowout quarterly results from Amazon which sent the stock higher. They explored Amazon's dominance over retail and the strength in its Amazon Web ... Show More
43m 49s
May 21
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica ... Show More
20m 12s